I'd reckon that part of this is related to how "easy" it is to get a drug approved for certain-death cancers. The barrier for a drug's approval is lower if the alternative is a certainty of painful death. This is sort of changing as we now seem to have plenty of those kinds of therapies, and the new goal is much more precise targeting of cancers (immunooncology is one example).